Connetics Corporation

Connetics Corporation is focused on the acquisition, development and commercialization of marketed and late-stageproducts. The Company's product and commercial focus is initially targeted at rheumatology and dermatology, two specialty medical markets. These commercially attractive markets have large patient populations yet relatively small physician

treating groups. U.S. dermatologists and rheumatologists write prescriptions each year exceeding $5.0 billion. The Company's goal is to leverage these markets by commercializing novel products to meet currently unmet medical needs

and employing focused and highly trained sales staff. Connetics currently markets Ridaura(R) (auranofin), a treatment for rheumatoid arthritis, and ACTIMMUNE(R) (interferon gamma-1b), a treatment for chronic granulomatous disease (beginning January 1999). On March 1, 1999 Connetics received clearance from the FDA to begin marketing Luxiq(TM) (betamethasone valerate) Foam, 0.12%, a product to treat corticosteroid-responsive scalp dermatoses. Connetics has several other products in development: ConXn(R) (recombinant human relaxin H2) ("relaxin"), targeting scleroderma, organ fibrosis, and infertility; and OLUX(TM) (clobetasol propionate) Foam, 0.05%, a novel formulation for the treatment of severe scalp dermatoses; and interferon gamma (through its wholly-owned subsidiary, InterMune Pharmaceuticals, Inc.) for the treatment of certain congenital, infectious and other diseases.

Contact Details: 3290 West Bayshore Road Palo Alto CA 94303 United States of America Tel: 650 843 2800 Fax: 650 843 2899 Email: WWW: www.connetics.com/

Loading...

Recent Publications by Connetics Corporation:
A novel foam vehicle for delivery of topical corticosteroids. Skin, particularly the uppermost layer--the stratum corneum--presents a...	11th November, 2005	Center for Skin Biology, Connetics Corp, Palo Alto, California 94303, USA.	J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S26-38. DOI Direct Link
Simultaneous determination of tretinoin and clindamycin phosphate and their degradation products in topical formulations by reverse phase HPLC. A new HPLC method based on reverse phase separation and photodiode-array...	9th October, 2004	Connetics Australia Pty. Ltd, 8 Macro Crt, Rowville, VIC 3178, Australia.	J Sep Sci. 2004 Jan;27(1-2):71-7.
Bioavailability of clobetasol propionate in different vehicles. Topical clobetasol propionate is widely used for the treatment of...	11th October, 2003	Connetics Corporation, Palo Alto, Calif., USA.	Skin Pharmacol Appl Skin Physiol. 2003 Jul-Aug;16(4):212-6. DOI Direct Link
Relaxin activates the MAP kinase pathway in human endometrial stromal cells. The reproductive hormone, relaxin, is structurally similar to insulin and...	26th November, 2002	Connetics Corporation, 3400 West Bayshore Rd., Palo Alto, California	J Cell Biochem. 2002;85(3):536-44. DOI Direct Link
Systemic administration of recombinant human relaxin (RHRLX) ameliorates the acute cyclosporine nephrotoxicity in rats. The reproductive hormone, relaxin, is structurally similar to insulin and...	16th March, 2001	Connetics Corporation, Palo Alto, CA, USA	J Heart Lung Transplant. 2001 Feb;20(2):253.
→View more Connetics Corporation research publications.

Press Releases on Connetics Corporation:
OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development	7th July, 2009	OncoMed Pharmaceuticals, Inc.	REDWOOD CITY, Calif., July 7 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the
Techne Corporation Announces That John L. Higgins has Accepted a Seat on Techne's Board	19th May, 2009	Techne Corporation	MINNEAPOLIS, May 19 /PRNewswire-FirstCall/ -- Techne Corporation (Nasdaq: TECH) today announced that Mr. John L. Higgins has accepted a position on Techne's Board of Directors and will also serve
Excaliard Pharmaceuticals Appoints Lincoln Krochmal, MD, President & Chief Executive Officer and Jeffrey Jenson, Head of Clinical Operations.	10th October, 2008	Excaliard Pharmaceuticals	CARLSBAD, Calif., Oct. 10 /PRNewswire/ -- Excaliard Pharmaceuticals, a late stage preclinical company developing targeted therapeutics for the treatment of dermatological disorders and fibrotic

Connetics Corporation Clinical Trials:
Acitretin and Etanercept in Psoriasis

Connetics Corporation Patents:
US Patent No.	Title
7222754	Aerosol system having lockable cap
5776459	TCR V beta 5 peptides
5811395	Relaxin analogs and derivatives methods and uses thereof
5911997	Relaxin-like factor and methods and uses thereof
6200953	Relaxin analogs and derivatives compositions
→View more Connetics Corporation patents.

Connetics Corporation (CNCT) Financial information Links from Barchart
CNCT Quote from from Barchart.com
CNCT Chart from from Barchart.com
CNCT Profile from from Barchart.com
CNCT Opinion from from Barchart.com
→View more Connetics Corporation finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 687 times since April 2007, the link to the organisation's website has been followed 128 times

Recent Search Terms used to find this page: CONNETICS - CA | connetics palo alto | connectics corthera | connetics relaxin | connetics relaxin | connetics corporation | connetics corporation | recent publications about techne corp | recent publications about techne corp | connetics corporation | .

Search for more companies in Palo Alto

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Connetics Corporation